Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer

Summary

Primary Objectives: 1. To examine the effect of celecoxib treatment on histological response, markers of proliferation (Ki-67), and apoptosis. Secondary endpoints include time to second primary or recurrence and survival. 2. To examine the toxicity associated with celecoxib administration in patients with previously treated Head and Neck Head and neck squamous cell carcinomas (HNSCC)or Non-small-cell lung carcinoma (NSCLC).

Timeline

Start

2005-09

Primary completion

2008-09

Completion

2008-09

Outcome

Outcome not reported

Stopped (Enrollment): “Termination due to poor accrual.”

Drugs

Indications